Clinical trials: MDI
Asthma
Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
Study to assess the efficacy and safety of four doses of budesonide inhalation aerosol (BD MDI, PT008) relative to placebo MDI in adult subjects with mild to moderate persistent asthma.
- Trial name
- NCT02105012
- Testing
- BD MDI 320 µg, BD MDI 160 µg, BD MDI 80 µg
- Where
- 41 sites in United States
- Volunteers
- 147 people
- Sponsor
- Pearl Therapeutics, Inc.
Asthma
Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management
The objective of the study was to compare the effectiveness, cost-effectiveness and direct healthcare costs of managing asthma in patients with evidence of persistent asthma, following the initiation and increased dose of inhaled…
- Trial name
- QvarAsthma (NCT01141439)
- Testing
- Extra-fine hydrofluoroalkane-beclomethasone dipropionate, Fluticasone propionate, Beclomethasone dipropionate
- Where
- United Kingdom
- Volunteers
- 815,377 people
- Sponsor
- Research in Real-Life Ltd
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
To compare the bronchodilator efficacy and safety of tiotropium inhalation capsules (18 µg once daily) and Atrovent® MDI (2 puffs of 20µg q.i.d.) among Filipino patients with COPD
- Trial name
- NCT02172469
- Testing
- Tiotropium inhalation powder capsule, Ipratropium Bromide Metered Dose Inhaler
- Volunteers
- 215 people
- Sponsor
- Boehringer Ingelheim
Asthma
Study to Evaluate the Pharmacokinetic Profile of Salbutamol Delivered by Unit Dose Dry Powder Inhaler (UD-DPI) Compared to the Diskus and Metered Dose Inhaler (MDI) in Healthy Volunteers.
This is an open-label, two part, six period- cross over, randomised, single dose, single centre study in healthy subjects. This is the first clinical study for the UD-DPI. This study is divided into two parts.
- Trial name
- NCT01984086
- Testing
- Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend), Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend), Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend)
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Mild Persistent Asthma
Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)
The aim of this exploratory investigation is to evaluate if the Forced Expiratory Volume in the 1st second (FEV1) measurements, fractional exhaled nitric oxide (FENO) and Provocative Concentration 20 (PC20) after Adenosine…
- Trial name
- NCT01343745
- Testing
- BDP/formoterol
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma, Cough Variant Asthma
Optimal Type of Inhaler in Cough Variant- or Cough Predominant Asthma
Asthma management is based on inhaled therapy, mainly on inhaled glucocorticosteroids (ICS). The efficacy of inhaled therapy depends on type of inhaler and proper inhalation skills.
- Trial name
- NCT04203472
- Testing
- Budesonid or budesonide/fomoterol administered by DPI, Budesonid or budesonide/fomoterol administered by MDI
- Where
- Poland
- Volunteers
- 22 people
- Sponsor
- Medical University of Warsaw
Schizophrenia, Schizoaffective Disorder
Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia
In this trial, researchers aim to investigate if prolonged-release melatonin can facilitate the withdrawal of chronic benzodiazepine administration in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Affective Disorder
- Trial name
- SMART (NCT01431092)
- Testing
- Melatonin
- Where
- Denmark
- Volunteers
- 86 people
- Sponsor
- Lone Baandrup
COPD
Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control
The purpose of this study is to evaluate the safety and efficacy of inhaled formoterol fumarate (7.2 and 9.6 µg ex-actuator) compared to placebo and Foradil Aerolizer in patients with moderate to very severe chronic obstructive…
- Trial name
- NCT01043601
- Testing
- Inhaled PT005, Formoterol Fumarate 12 µg (Foradil Aerolizer)
- Where
- United States
- Sponsor
- Pearl Therapeutics, Inc.
Bronchospasm
A First Time In Human Study To Assess The Compound GSK615915
GSK615915A is being developed as a novel surfactant for use in the formulation of GSK's future generation of Metered Dose Inhalers (MDIs).
- Trial name
- NCT00400660
- Testing
- GSK615915A
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma, Bronchospasm
Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics
This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA-MDI (E004), using a stable isotope deuterium-labeled epinephrine (epinephrine-d3) to differentiate the…
- Conditions
- Asthma, Bronchospasm, Wheezing, Shortness of Breath
- Trial name
- NCT01188577
- Testing
- Epinephrine Inhalation Aerosol, HFA, Epinephrine Inhalation Aerosol
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Major Depressive Disorder
Lithium Versus Paroxetine in Patients With Major Depression Who Have a Family History of Bipolar Disorder or Suicide
This study is being done to look at how well people respond to two very different drug treatments for depression. Clinically, people with depression can respond differently to drug treatments for reasons which are not always…
- Trial name
- NCT00400088
- Testing
- paroxetine, lithium
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Nova Scotia Health Authority
Asthma
Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use
The study is conducted to evaluate the potentially improved patient handling of the ELLIPTA Dry Powder Inhaler (DPI). Therefore, the study aims to evaluate errors encountered by subject with asthma during handling ELLIPTA DPI…
- Trial name
- NCT02794480
- Testing
- ELLIPTA DPI, GSK MDI, AZ MDI
- Where
- 20 sites in United States
- Volunteers
- 324 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
PT003 MDI Cardiovascular Safety Study
This study is primarily a safety study. The primary and secondary endpoints are based on 24-hour Holter monitor assessments obtained on Day 14 relative to baseline.
- Trial name
- NCT01349803
- Testing
- PT005 MDI, PT001 MDI, PT003 MDI
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 237 people
- Sponsor
- Pearl Therapeutics, Inc.
Asthma
Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).
The purpose of this study is to evaluate the level of satisfaction experienced by asthma or chronic obstructive pulmonary disease (COPD) patients when using the Fluticasone/Salmeterol HFA Metered Dose Inhaler (MDI) with counter…
- Trial name
- NCT00404261
- Testing
- Fluticasone/Salmeterol HFA
- Where
- 4 sites in Australia
- Volunteers
- 132 people
- Sponsor
- GlaxoSmithKline
Bipolar Disorder, Anxiety Disorders
Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder
Pediatric Bipolar Disorder (BD) is uncommon in children. Its symptoms include periods of manic behavior (being overly happy or giddy, feeling grandiose, feeling a decreased need for sleep, having too much energy, moving more than…
- Conditions
- Bipolar Disorder, Anxiety Disorders, Bipolar Affective Disorder, Bipolar Depression
- Trial name
- NCT00805493
- Testing
- Riluzole
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Mental Health (NIMH)
Asthma
BI 671800 in Asthmatic Patients on Inhaled Corticosteroids
This is a 6 week study to assess the effect of BI 671800 in patients with asthma. It is a double blind, parallel arm trial testing the safety and efficacy of BI 671800. The main objective is to assess the effect on lung function.
- Trial name
- NCT01103349
- Testing
- BI 671800, Montelukast
- Where
- 53 sites in United States, Austria and 7 more
- Volunteers
- 243 people
- Sponsor
- Boehringer Ingelheim
Asthma
Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients
The primary objective of this study is to evaluate the effect of Beclomethasone dipropionate HFA on small airways compared to Fluticasone propionate powder for inhalation administered twice daily to poorly controlled asthmatics.
- Trial name
- NCT00071552
- Testing
- Qvar, Flovent Diskus
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
COPD
24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI
Randomized, Phase IIIb, Two-period, Two-treatment Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects with Moderate to Very Severe COPD after 4 Weeks of Treatment with PT003 and…
- Trial name
- NCT02347085
- Testing
- GFF MDI (PT003)
- Volunteers
- 43 people
- Sponsor
- Pearl Therapeutics, Inc.
Depression, Depressive Symptoms
The Use of Major Depression Inventory (MDI) in Measuring Preoperative Depressive Symptoms in Breast Cancer Patients
The purpose of this study is to measure depressive symptoms in breast cancer patients before surgery with Major Depression Inventory (MDI).
- Trial name
- NCT01284751
- Testing
- MDI - self-rating inventory
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Herlev Hospital
Chronic Obstructive Pulmonary Disease
PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD
The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.
- Trial name
- NCT01566773
- Testing
- PT001 MDI, Tiotropium Bromide
- Where
- 10 sites in United States
- Volunteers
- 140 people
- Sponsor
- Pearl Therapeutics, Inc.